Development, Commercialization and Supply Agreement - Additional Information (Detail)	1 Months Ended									3 Months Ended		12 Months Ended
	Feb. 28, 2023 USD ($)	Jan. 31, 2023 USD ($)	Jan. 31, 2022 USD ($)	Feb. 29, 2020 USD ($)	Jan. 31, 2020 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Mar. 31, 2016 USD ($)	Feb. 28, 2015 USD ($)	Mar. 31, 2023 USD ($) Item	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2021 USD ($)
License And Collaboration Agreements [Line Items]
Revenue recognized related to upfront and milestone payments										$ 445,000	$ 372,000
Licenses revenue										85,975,000	94,630,000
Deferred revenue										14,901,000	16,337,000	$ 15,346,000		$ 16,709,000
Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue										84,654,000	93,986,000
CSL Seqirus | Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received	$ 500,000
Licenses revenue										$ 500,000		0
Upfront payment receivable	500,000
Event-related milestone payments receivable	8,000,000.0
Additional product-related milestone payments receivable	$ 4,000,000.0
Mochida | In-licenses
License And Collaboration Agreements [Line Items]
Milestones payment		$ 1,000,000.0	$ 1,000,000.0
Mochida | In-licenses | Research and Development Expense
License And Collaboration Agreements [Line Items]
Upfront payment													$ 2,700,000
Edding | Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received									$ 15,000,000.0
Number of indications of the regulatory milestone events relating to the submission and approval | Item										3
Amounts to be received upon achievement of the regulatory milestone events										$ 33,000,000.0
Sales-based milestone event payment										120,000,000.0
Revenue recognized related to upfront and milestone payments										300,000	200,000
Deferred revenue										9,000,000.0		9,300,000
Edding | Out-licenses | Licensing Revenue
License And Collaboration Agreements [Line Items]
Licenses revenue										8,000,000.0		7,700,000
Edding | Out-licenses | Maximum
License And Collaboration Agreements [Line Items]
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone										153,000,000.0
Amounts to be received upon achievement of the regulatory milestone events										15,000,000.0
Sales-based milestone event payment										50,000,000.0
Edding | Out-licenses | Minimum
License And Collaboration Agreements [Line Items]
Amounts to be received upon achievement of the regulatory milestone events										2,000,000.0
Sales-based milestone event payment										5,000,000.0
Edding | Out-licenses | Clinical Trial Application
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received								$ 1,000,000.0
Biologix FZCo | Out-licenses
License And Collaboration Agreements [Line Items]
Revenue recognition period of non-refundable up-front payment								10 years
Biologix FZCo | Out-licenses | Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue										300,000	0
HLS | Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received							$ 5,000,000.0
Non-refundable milestone payment received				$ 2,500,000	$ 3,800,000	$ 2,500,000
Revenue recognized related to upfront and milestone payments										100,000	100,000
Deferred revenue										5,400,000		5,600,000
Non-refundable up-front received period							6 months
Non-refundable milestone payment received							$ 3,800,000
HLS | Out-licenses | Health Canada
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received							2,500,000
HLS | Out-licenses | Licensing Revenue
License And Collaboration Agreements [Line Items]
Licenses revenue										8,300,000		$ 8,200,000
HLS | Out-licenses | Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue										$ 1,600,000	$ 0
HLS | Out-licenses | Maximum
License And Collaboration Agreements [Line Items]
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone							50,000,000.0
HLS | Out-licenses | Achievement of REDUCE-IT Trial
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received							$ 2,500,000